Forus has successfully raised $150 million in a Series C funding round. The round was led by the investment fund Bain Capital Ventures, with participation from existing investors who provided additional support. Other participants in the round included Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel.
This funding values Forus at $3 billion, representing a threefold increase from its previous valuation. As a result of this round, the total amount of funds received by Forus exceeds $300 million. Bain Capital Ventures has supported the company since its seed round.
Forus is developing an artificial intelligence-based network designed to improve access to medicines. Its platform connects doctors, pharmacies, payers, and biopharmaceutical companies. The company plans to use the raised funds to scale its platform nationwide and increase investments in technology and talent.
Forus utilizes AI agents to manage the process after physicians prescribe medication. These agents navigate insurance requirements and financial assistance programs, as well as coordinate processes in pharmacies and supply chains. Each prescription is processed by a separate AI agent that analyzes patient information before determining the next necessary step, relying on clinical models and specialized sub-agents. The company's technology is trained on data from millions of past cases.
The primary goal of the platform is to reduce delays between prescribing treatment and receiving it. This should enable doctors to prescribe newer medications with greater confidence. It is noted that one in three patients prescribed expensive or complex drugs never receives the first dose.
Forus aims to eliminate these obstacles through workflow automation. Meanwhile, the service remains free for both providers and patients. Currently, the platform supports providers in all 50 US states and covers 85% of US zip codes. The company intends to move beyond its initial specialization and begin working in additional areas of medicine. More than a third of providers in the US have already implemented the platform in their primary area of specialization, and adoption is growing in several other areas.
The company plans to expand the scope of its AI agents so they cover most of the treatment journey, including processes beyond simple prescription fulfillment. Forus is also collaborating with pharmaceutical and biotechnology firms. The company currently engages with nine out of the fifteen largest global biopharmaceutical companies and supports a number of fast-growing biotech enterprises. These partnerships give Forus insight into the barriers affecting patients and doctors, allowing the company to improve access to care and link drug development with real-world treatment experience.
The new investment provides Forus with significant capital for the next phase of growth. CEO Sahir Jaggi stated the company's ambition to implement its platform in every physician's clinic in the US. Forus believes that the pace of medical advancement is constantly accelerating, yet patients can still face difficulties accessing new treatments. The company aims to close this gap through AI-driven coordination that connects multiple parties in the drug delivery process.
Investor Bain Capital Ventures views Forus as becoming an important infrastructure platform in healthcare. The latest funding also highlights the growing investor interest in healthcare automation. Companies using AI are increasingly focusing on overcoming administrative barriers in medical care. Moving forward, Forus will focus on expanding technology and workforce, as well as increasing coverage across medical specialties and care settings.